Cantor Fitzgerald Upgrades Catalyst Pharmaceuticals (NASDAQ:CPRX) to “Strong-Buy”
Catalyst Pharmaceuticals (NASDAQ:CPRX – Get Free Report) was upgraded by stock analysts at Cantor Fitzgerald to a “strong-buy” rating in a research note issued to investors on Thursday,Zacks.com reports. CPRX has been the subject of several other reports. HC Wainwright reissued a “buy” rating and set a $35.00 price target on shares of Catalyst Pharmaceuticals […]
More Stories
US Border Patrol to Charge $5,000 Apprehension Fee for Illegal Border Crossers
By Aldgra Fredly The U.S. Border Patrol announced on Dec. 5 that it will impose a $5,000 apprehension fee on...
Bobby Lee’s Net Worth And His Journey To Success
One of the oldest comedians from the US, Bobby Lee, has spent around 30 years in the field of comedy,...
UK Sanctions Russia After Inquiry Holds Putin Responsible for 2018 Novichock Poisonings
By Guy Birchall The UK issued new sanctions on Russia on Dec. 4, after a public inquiry into the death...
Indiana House Passes New Congressional Map Favoring Republicans
By Arjun Singh The Indiana House of Representatives on Dec. 5 passed a bill that would revise the state’s maps...
Economists Forecast Stronger US Growth, Lingering Inflation in 2026
By Tom Ozimek The U.S. economy will grow faster next year than previously projected and inflationary pressures will tick down,...
Noem Says US Travel Ban to Expand to Over 30 Countries
By Aldgra Fredly Homeland Security Secretary Kristi Noem said on Dec. 4 that the Trump administration is looking to increase...